Nanologica AB (publ)

Stockholm Stock Exchange NICA.ST

Nanologica AB (publ) Capital Expenditure for the year ending December 31, 2023: USD -2.07 M

Nanologica AB (publ) Capital Expenditure is USD -2.07 M for the year ending December 31, 2023, a -153.37% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Nanologica AB (publ) Capital Expenditure for the year ending December 31, 2022 was USD -817.29 K, a -2.40% change year over year.
Nanologica AB (publ) Capital Expenditure for the year ending December 31, 2021 was USD -798.11 K, a -0.94% change year over year.
Nanologica AB (publ) Capital Expenditure for the year ending December 31, 2020 was USD -790.71 K, a 76.04% change year over year.
Nanologica AB (publ) Capital Expenditure for the year ending December 31, 2019 was USD -3.30 M, a -884.84% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: NICA.ST

Nanologica AB (publ)

CEO	Mr. Andreas Bhagwani
IPO Date	Oct. 30, 2015
Location	Sweden
Headquarters	Forskargatan 20G
Employees	16
Sector	Health Care
Industries Biotechnology Chemicals & Advanced Materials Petrochemicals Pharmaceuticals

Description

Nanologica AB (publ), a nanotechnology company, develops nanoporous silica for applications in the life science industry. The company offers nanoporous silica particles for drug development and chromatography separation. It provides NLAB Silica, a technology platform for drug delivery; NLAB Spiro, an inhalation platform for pulmonary drug delivery; SVEA (U)HPLC analytical columns; and preparative chromatography. Nanologica AB (publ) was founded in 2004 and is based in Södertälje, Sweden.

Key trends

Past 5 years